Mesenchymal Stem Cells and Extracellular Vesicles: Therapeutic Potential in Organ Transplantation
Table 1
Recent summary of the clinical practice of MSCs and MSC-EVs in organ transplantation.
Source
Occasion
Type
Result
References
Autologous BM-MSC
Postoperative
Hematopoietic stem cell transplantation
It has been determined that administering autologous MSCs four times a week is safe for the treatment of refractory GVHD after malignant hematological disease HCT
Peripheral blood immune cells in kidney transfer recipients after mesenchymal stem cell therapy and tacrolimus discontinuity may help improve therapeutic strategies using mesenchymal stem cells to reduce the use of calcium inhibitors
Prove that MSC treatment combined with early cessation of CNI is associated with better blood pressure control, reversal of left ventricular hypertrophy, and prevention of progressive diastolic dysfunction after kidney transplantation
Preoperative infusion of MSC in liver transplant recipients is safe and causes mild positive changes in immunomodulatory T cells and NK cells in peripheral blood
In organ transplantation, the type of mesenchymal stem cells and MSC-EVs and the timing of treatment are critical. The table provides a summary of the methods currently used in clinical trials and animal studies.